DCTH icon

Delcath Systems

16.28 USD
+0.00
0.00%
At close Feb 14, 4:00 PM EST
After hours
16.43
+0.15
0.92%
1 day
0.00%
5 days
-0.73%
1 month
28.29%
3 months
76.38%
6 months
121.20%
Year to date
29.10%
1 year
245.65%
5 years
112.53%
10 years
-100.00%
 

About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Employees: 76

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

740% more call options, than puts

Call options by funds: $3.28M | Put options by funds: $390K

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

31% more funds holding

Funds holding: 52 [Q2] → 68 (+16) [Q3]

10% more capital invested

Capital invested by funds: $81.7M [Q2] → $89.6M (+$7.85M) [Q3]

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

1.49% less ownership

Funds ownership: 38.12% [Q2] → 36.63% (-1.49%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$21
29%
upside
Avg. target
$22
32%
upside
High target
$22
35%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Craig-Hallum
Chase Knickerbocker
46% 1-year accuracy
12 / 26 met price target
29%upside
$21
Buy
Maintained
17 Jan 2025
HC Wainwright & Co.
Swayampakula Ramakanth
33% 1-year accuracy
65 / 195 met price target
35%upside
$22
Buy
Reiterated
14 Jan 2025

Financial journalist opinion

Based on 6 articles about DCTH published over the past 30 days

Neutral
Business Wire
2 days ago
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of metastatic uveal melanoma (mUM). Our proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System.
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
Positive
Zacks Investment Research
6 days ago
Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 33.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet
Negative
Yahoo Finance
2 weeks ago
Biotech walks a 'tightrope' amid unclear funding, regulations
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway.
Biotech walks a 'tightrope' amid unclear funding, regulations
Positive
Zacks Investment Research
2 weeks ago
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
Neutral
Business Wire
2 weeks ago
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 11-12, 2025 at The Cliff Lodge in Snowbird, UT. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focu.
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Positive
Zacks Investment Research
1 month ago
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
Neutral
Business Wire
1 month ago
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024. Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $15.1 million and $37.2 million, respe.
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
Neutral
Business Wire
1 month ago
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of an individual whose employment commenced on November 4, 2024. The grant totaled the right to purchase 30,000 shares of the Company.
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 month ago
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August 2019 as a component of a private placement, h.
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
Charts implemented using Lightweight Charts™